Company profile

AlveoliX AG company profile

AlveoliX provides in-vitro solutions based on proprietary and unique organ-on-chip technologies aimed at improving preclinical decision-making and thus reducing drug development costs. AlveoliX aims at changing the way drug development research is done today by providing in-vitro models that reproduce the in-vivo environment in an unprecedented way. These in-vitro models, called organ-on-chips, will make it possible to better predict drugs’ responses in humans than standard in-vitro and in-vivo models and as a consequence to importantly reduce animal testing.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
00011-00050 employees
Revenue range
$50K+
Founded
2019-01-01

Headquarters

Headquarters
Bulle, Fribourg, Switzerland
Postal code
3010
Country code
CH
Continent
Europe

Capital profile

Funding and company signals

Funding rounds
3
Last funding
Grant / 2019-03-19
Investors
1
Lead investors
1
Founders
1
Articles
2

Founders and investors

Founders

Janick Stucki

Lead investors

Eurostars

Investors

Eurostars

People at this company

Preview only. Contact details are available after you sign in.

Log in to view people and contact details at this company

Contact information and company affiliations may no longer be accurate. Verify details before reaching out.

Shipment data

Explore detailed shipment data

Sign in to view shipment history, products, suppliers, and trade lanes for this company.

Log in to view shipment data

Shipment records and coverage can change as the dataset is updated.